Research delves into the little-explored world of the infant oral microbiome, examining how early nutrition and environmental factors shape it. With implications for lifelong health, the research aims to guide future health recommendations, emphasizing the need for more longitudinal studies and advanced sequencing techniques.
Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share – Biotech Investments
Marinomed Biotech AG / Key word(s): Corporate Action/Capital Increase Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer
September 19, 2024